Drug Profile
BR 101801
Alternative Names: BR-101801Latest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA activated protein kinase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies
- Preclinical Colorectal cancer
Most Recent Events
- 09 Dec 2023 Updated efficacy and adverse event data from a phase I trial in Hematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 09 Dec 2023 Boryung Pharmaceutical plans to initiate a phase II trial for peripheral T cell lymphoma and Nodal T-follicular helper cell lymphomain
- 02 Jul 2023 Phase-I development is ongoing for Hematological malignancies in South Korea (NCT04018248)